158 related articles for article (PubMed ID: 3488068)
21. Adoptive immunotherapy of malignant diseases with IL-2-activated lymphocytes.
Kimoto Y; Taguchi T
Biken J; 1987 Jun; 30(2):29-38. PubMed ID: 3501954
[TBL] [Abstract][Full Text] [Related]
22. [Lymphokine-activated killer (LAK) adoptive immunotherapy: optimal method for large-scale LAK induction].
Nii A; Sone S; Okubo A; Fawzy F; Yanagawa H; Ogura T
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1871-6. PubMed ID: 3496049
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
Rosenberg SA; Mulé JJ
Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
[TBL] [Abstract][Full Text] [Related]
24. Interleukin 2-activated cytotoxic lymphocytes in cancer therapy.
Grimm EA; Jacobs SK; Lanza LA; Melin G; Roth JA; Wilson DJ
Symp Fundam Cancer Res; 1986; 38():209-19. PubMed ID: 3489259
[TBL] [Abstract][Full Text] [Related]
25. [Adoptive immunotherapy of malignant diseases with LAK cells].
Kimoto Y; Tanji Y; Tanaka T; Taguchi T
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):687-92. PubMed ID: 3493732
[TBL] [Abstract][Full Text] [Related]
26. Lymphokine-activated killer cell expansion for clinical trials of adoptive immunotherapy with interleukin-2: optimization of the culture technique.
Favrot MC; Coze C; Combaret V; Gaspard M; Colin C; Franks C; Negrier S; Philip I; Philip T
Mol Biother; 1990 Mar; 2(1):32-7. PubMed ID: 2185792
[TBL] [Abstract][Full Text] [Related]
27. [Studies on adoptive immunotherapy using recombinant interleukin 2].
Sugiyama Y; Takao H; Saji S; Sakata K
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1307-13. PubMed ID: 3488028
[TBL] [Abstract][Full Text] [Related]
28. [Induction of LAK cells and CTL in patients with brain tumor and research of its clinical application].
Moriki A
Nihon Geka Hokan; 1989 Jan; 58(1):107-18. PubMed ID: 2802908
[TBL] [Abstract][Full Text] [Related]
29. [Adoptive immunotherapy by intra-arterial infusion of ATLAK or Allo-TLAK cells in patients with head and neck cancer].
Ikawa T; Eura M; Fukiage T; Murakami H; Yamasaki S; Fukuda K; Fukushima M; Arishima S; Maehara T; Ishikawa T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1438-47. PubMed ID: 2786378
[TBL] [Abstract][Full Text] [Related]
30. [LAK cells and cancer].
Taguchi T; Kimoto Y
Gan To Kagaku Ryoho; 1986 Dec; 13(12):3327-33. PubMed ID: 3539024
[TBL] [Abstract][Full Text] [Related]
31. [Adoptive immunotherapy of malignant disease using LAK cells].
Kimoto Y; Taguchi T
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):788-96. PubMed ID: 3260466
[TBL] [Abstract][Full Text] [Related]
32. [Bronchial arterial infusion of lymphokine-activated killer cells stimulated by autologous tumor cells].
Kimura H; Yamaguchi Y; Obata S; Yusa T; Sekine Y
Gan To Kagaku Ryoho; 1988 Aug; 15(8 Pt 2):2401-4. PubMed ID: 3137876
[TBL] [Abstract][Full Text] [Related]
33. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
Mulé JJ; Shu S; Rosenberg SA
J Immunol; 1985 Jul; 135(1):646-52. PubMed ID: 3889158
[TBL] [Abstract][Full Text] [Related]
34. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213
[TBL] [Abstract][Full Text] [Related]
35. [Effects of serum immunosuppressive factors on the cytotoxicity of lymphokine-activated killer (LAK) cells induced by recombinant interleukin 2(R-IL2)].
Takao H; Saji S; Sugiyama Y; Tachibana S; Goshima H; Kunii Y; Sakata K
Nihon Geka Gakkai Zasshi; 1988 Jul; 89(7):992-8. PubMed ID: 2975748
[TBL] [Abstract][Full Text] [Related]
36. Lymphokine activated killer (LAK) cell-mediated endothelial injury: a mechanism for capillary leak syndrome in patients treated with LAK cells and interleukin-2.
Kotasek D; Vercellotti GM; Ochoa AC; Bach FH; Jacob HS
Trans Assoc Am Physicians; 1987; 100():21-7. PubMed ID: 3502662
[TBL] [Abstract][Full Text] [Related]
37. The cellular immunotherapy of primary brain tumors.
Hayes RL
Rev Neurol (Paris); 1992; 148(6-7):454-66. PubMed ID: 1448666
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
Rosenberg SA
J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
[TBL] [Abstract][Full Text] [Related]
39. [Adoptive immunotherapy of malignant diseases using normal allogeneic LAK cells].
Kimoto Y; Tanji Y; Tanaka T; Taguchi T
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1884-9. PubMed ID: 3496050
[TBL] [Abstract][Full Text] [Related]
40. [Transfer of interleukin 2-activated lymphocytes].
Kohgo Y
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 2):2127-34. PubMed ID: 3496856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]